Antibodies in late-stage clinical studies

The remarkable increase in the number of antibody therapeutics in late-stage clinical studies that occurred between 2010 and 2022 has been documented in the ‘Antibodies to watch‘ article series, which describes monoclonal antibodies in late-stage clinical studies (i.e., pivotal Phase 2, Phase 2/3 or Phase 3). All articles in the series were published in mAbs, and they are all freely available.

The table below is derived from data included in the latest article in the series, Antibodies to Watch in 2024, published in January 2023. The Antibody Society will update the data every quarter during 2023. Last table update: December 1, 2024.
Data for antibody therapeutic products that have advanced to regulatory review or approval in any country have been excluded from this table, but they are included in a searchable table that can be found here.

Biosimilar antibodies have been excluded from both tables.

Format and Fc modification data were compiled by Drs. Alicia Chenoweth and Silvia Crescioli, King’s College London, who also built the data table below.

Please cite our data as follows: The Antibody Society. Antibody therapeutics in late-stage clinical studies. (date accessed); www.antibodysociety.org/antibodies-in-late-stage-clinical-studies/

The table below is an interactive table that can be filtered based on multiple conditions. Please use the filtering criteria above the table and type in the search boxes in the header of each column.

Scroll right to see all the columns.

Drug Code(s)	INN	Target	Format	Specificity	Sequence source	Isotype (Fc)	Light Chain	Conjugated/Fused	Linker	Payload/Fused moiety	Fc Mutations/Modifications	Phase of Clinical Development	Late-stage Clinical Study Indications	Therapeutic Area	Company	Licensee/Partner
9MW2821		Nectin-4	Full length Ab conjugate	Monospecific	Humanized	IgG1	kappa	ADC	Valine-Citrulline (Cleavable linker)	Tubulin inhibitor, Monomethyl auristatin E (MMAE)	TBD	Phase 3	Urothelial carcinoma (NCT06196736 / CTR20234024, NCT06592326), Cervical Cancer (NCT06692166)	Cancer	Mabwell (Shanghai) Bioscience Co. Ltd.
AB154	Domvanalimab	TIGIT	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			L234A, L235A (impair Fc effector functions)	Phase 3	Gastrointestinal tract adenocarcinoma (NCT05568095); Non-small cell lung cancer (NCT05211895, NCT05502237, NCT04736173)	Cancer	Arcus Biosciences Inc.	Gilead Sciences, Taiho Pharma
ABBV-151, ARGX-115, PR-1762844	Livmoniplimab	GARP/TGF beta complex	Full length Ab	Monospecific	Chimeric / Humanized	IgG4	kappa	Unconjugated			S228P (hinge stabilization)	Phase 2/3	Non-small cell lung cancer (NCT06236438), Hepatocellular Carcinoma (NCT06109272)	Cancer	argenx	Eli Lilly and Company
ABBV-181	Budigalimab	PD-1	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			L234A, L235A (impair Fc effector functions)	Phase 2/3	Non-small cell lung cancer (NCT06236438), Hepatocellular Carcinoma (NCT06109272)	Cancer	AbbVie
ABBV-383, TNB-383B		BCMA, CD3	Fragment-Fc - Fab-h-CH2-CH3 x VH-VH-h-CH2-CH3	Bispecific	Human	IgG4	kappa	Unconjugated			TBD	Phase 3	Multiple myeloma (NCT06158841)	Cancer	Amgen	AbbVie
ABBV-400	Telisotuzumab adizutecan	cMET	Full length Ab	Monospecific	Humanized	IgG1	kappa	ADC	Valine-Alanine	Topoisomerase I inhibitor, Camptothecin	TBD	Phase 3	Colorectal cancer (NCT06614192)	Cancer	Pierre Fabre	AbbVie
ABBV-IMAB-TJC4, TJ011133, TJ133, TJC4	Lemzoparlimab	CD47	Full length Ab	Monospecific	Human	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 3	Myelodysplastic Syndromes (MDS) (NCT05709093)	Cancer	I-Mab Biopharma Co. Ltd.
ABC008	Ulviprubart	KLRG1	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			Afucosylated (improve FcγRIIIa binding/improve ADCC)	Phase 2/3	Inclusion Body Myositis (NCT05721573, NCT06450886)	Immune-mediated / inflammatory disorders	Abcuro Inc.
ABT-981	Lutikizumab	IL-1 alpha, IL-1 beta	Appended Ig - 2+2 symmetric, DVD-Ig	Bispecific	Humanized	IgG1	kappa	Unconjugated			L234A, L235A (impair Fc effector functions)	Phase 3	Hidradenitis Suppurativa (NCT06468228)	Immune-mediated / inflammatory disorders	AbbVie
ACT017	Glenzocimab	GP VI	Fragment - Fab	Monospecific	Humanized	NA	kappa	Unconjugated			None found	Phase 2/3	Acute ischemic stroke (NCT05070260, NCT05559398)	Cardiovascular / hemostasis disorders	Acticor Biotech
AGEN1181	Botensilimab	CTLA-4	Full length Ab	Monospecific	Human	IgG1	kappa	Unconjugated			S239D, A330L, I332E (enhanced effector function)	Phase 2 pivotal	Colorectal cancer (NCT05608044)	Cancer	Agenus Inc.
AGEN2034	Balstilimab	PD-1	Full length Ab	Monospecific	Human	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 2 pivotal	Metastatic Colorectal Cancer (NCT05608044)	Cancer	Agenus Inc.	Betta Pharmaceuticals, Recepta biopharma
AK109	Pulocimab	VEGFR2	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			None found	Phase 3	Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma (NCT06341335 / CTR20241225)	Cancer	Akesobio Australia Pty Ltd
AK111	Gumokimab	IL-17A	Full length Ab	Monospecific	TBD	IgG1	kappa	Unconjugated			None found	Phase 3	Plaque psoriasis (CTR20230111 / NCT06066125); ankylosing spondylitis (NCT06378697)	Immune-mediated / inflammatory disorders	Akesobio Australia Pty Ltd
AK117	Ligufalimab	CD47	Full length Ab	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge stabilization)	Phase 3	Head & neck cancer (NCT06601335)	Cancer	Akesobio Australia Pty Ltd
AK120	Manfidokimab	IL-4R alpha	Full length Ab	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 3	Atopic dermatitis (NCT06383468)	Immune-mediated / inflammatory disorders	Akesobio Australia Pty Ltd
ALXN1720	Gefurulimab	Complement C5, albumin	Fragment - sdAb, VHH-VHH'	Bispecific	Humanized	NA	NA	Unconjugated			NA	Phase 3	Generalized myasthenia gravis (NCT05556096, NCT06607627 not yet recruiting)	Immune-mediated / inflammatory disorders	AstraZeneca
ALXN2220, NI006, NI301A		Amyloid transthyretin	Full length Ab	Monospecific	Human	IgG1	TBD	Unconjugated			TBD	Phase 3	Transthyretin amyloid cardiomyopathy (NCT06183931)	Cardiovascular / hemostasis disorders	Neurimmune AG	AstraZeneca
ANB019	Imsidolimab	IL-36R	Full length Ab	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 3	Generalized pustular psoriasis (NCT05352893)	Immune-mediated / inflammatory disorders	AnaptysBio Inc.
AntiBKV, MTX-005, mAb129		BK virus	Full length Ab	Monospecific	Human	TBD	TBD	Unconjugated			TBD	Phase 2/3	BK Viremia (NCT05769582)	Infectious diseases	Memo Therapeutics AG
ANX005		Complement C1q	Full length Ab	Monospecific	Humanized	IgG4	kappa	Unconjugated			None found	Phase 3	Guillain-Barré syndrome (NCT04701164)	Muscular disorders	Annexon Inc.
ANX007		Complement C1q	Fragment - Fab	Monospecific	Humanized	NA	kappa	Unconjugated			NA	Phase 3	Geographic Atrophy (NCT06510816)	Ophthalmic disorders	Annexon Inc.
AR-301, KBSA301	Tosatoxumab	S. aureus alpha toxin	Full length Ab	Monospecific	Human	IgG1	lambda	Unconjugated			None found	Phase 3	Ventilator-associated pneumonia caused by S. aureus (NCT03816956)	Infectious diseases	Kenta Biotech Ltd	Aridis Pharmaceuticals, Serum AMR, Shenzhen Arimab Biopharmaceuticals Co. Ltd.
ARX788, JNJ-0683, NCB-001	Anvatabart opadotin	HER2	Full length Ab conjugate	Monospecific	Humanized	IgG1	kappa	ADC	Oxime (Non-cleavable linker)	Tubulin inhibitor, Amberstatin 269 (Auroxime)	A114pAF (non-natural amino acid for site specific conjugation)	Phase 3	Breast cancer (NCT05426486)	Cancer	Johnson & Johnson	NovoCodex, Zhejiang Medicine Co. Ltd
ASKB589		Claudin-18.2	Full length Ab	Monospecific	Humanized	IgG1	TBD	Unconjugated			TBD	Phase 3	Gastric or gastroesophageal junction adenocarcinoma (NCT06206733 / CTR20233416)	Cancer	Jiangsu Aosaikang Pharmaceutical Co. Ltd.
AV299, SCH900105	Ficlatuzumab	HGF	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			None found	Phase 3	Head and neck cancer (NCT06064877)	Cancer	LG Chem Ltd.	Biodesix
AZD0486, TNB-486		CD19, CD3	Fragment-Fc	Bispecific	TBD	IgG4	TBD	Unconjugated			Hinge stabilized, Fc silenced, knob in a hole heterodimerization strategy	Phase 3	Follicular lymphoma (NCT06549595)	Cancer	AstraZeneca
AZD0901, CMG901, MRG005		Claudin-18.2	Full length Ab conjugate	Monospecific	TBD	TBD	TBD	ADC	Cleavable linker	Tubulin inhibitor, Monomethyl auristatin E (MMAE)	TBD	Phase 3	Gastric Cancer and Gastroesophageal Junction Cancer (NCT06346392)	Cancer	LEPU Biopharma, Shanghai Miracogen Inc.	AstraZeneca, Keymed Biosciences Inc.
AZD2936	Rilvegostomig	PD-1, TIGIT	Full length Ab	Bispecific	Humanized	IgG1	kappa/lambda	Unconjugated			L234F/L235E/P331S (reduced effector function), S354C/T366W (knob) and Y349C/T366S/L368A/Y407V (hole) (heavy chain heterodimerization)	Phase 3	Biliary tract cancer (NCT06109779, NCT06467357), Non-Small Cell Lung Cancer (NCT06357533, NCT06564844, NCT06692738 not yet recruiting), Non-squamous Non-Small Cell Lung Cancer (NCT06627647 not yet recuiting)	Cancer	AstraZeneca	Compugen Ltd.
B001		CD20	TBD	Monospecific	Humanized	TBD	TBD	Unconjugated			TBD	Phase 2/3	Neuromyelitis optica (NCT06413654 / CTR20241605)	Immune-mediated / inflammatory disorders	Shanghai Pharmaceuticals Holding
B007		CD20	TBD	Monospecific	Humanized	TBD	TBD	Unconjugated			TBD	Phase 2/3	Pemphigus (NCT06454357 / CTR20240985), Generalized Myasthenia Gravis (NCT06447597), Primary membranous nephropathy (NCT06470191)	Immune-mediated / inflammatory disorders	Shanghai Jiaolian Drug Research and Development Co. Ltd
BAT1308		PD-1	Full length Ab	Monospecific	Humanized	IgG4	TBD	Unconjugated			TBD	Phase 2/3	Cervical cancer (NCT06123884 / CTR20232394), Endometrial Cancer (NCT06321068)	Cancer	Bio-Thera Solutions Ltd.
BAT4406F		CD20	Full length Ab	Monospecific	TBD	TBD	TBD	Unconjugated			TBD	Phase 2/3	Neuromyelitis optica spectrum disorder (CTR20231610)	Immune-mediated / inflammatory disorders	Bio-Thera Solutions Ltd.
BAT5906		VEGF-A	Full length Ab	Monospecific	TBD	IgG1	kappa	Unconjugated			None found	Phase 3	Neovascular (Wet) Age-related Macular Degeneration (NCT05439629)	Ophthalmic disorders	Bio-Thera Solutions Ltd.
BGB-A1217	Ociperlimab	TIGIT	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			None found	Phase 3	Non-small cell lung cancer (NCT04746924)	Cancer	BeiGene Ltd.
BIIB059	Litifilimab	BDCA2	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			None found	Phase 3	Cutaneous lupus erythematosus (NCT05531565, NCT06044337); Systemic lupus erythematosus (NCT05352919, NCT04961567, NCT04895241)	Immune-mediated / inflammatory disorders	Biogen
BL-B01D1	Izalontamab brengitecan	EGFR, HER3	Appended Ig conjugate - 2+2 symmetric, IgG-(scFv)2	Bispecific	TBD	IgG1	kappa/lambda	ADC	Cathepsin B (Cleavable linker)	Topoisomerase I inhibitor, Ed-04	None found	Phase 3	Nasopharyngeal carcinoma (NCT06118333 / CTR20233419); Esophageal Squamous Cell Carcinoma (NCT06304974), Small Cell Lung Cancer (NCT06500026), Non-small Cell Lung Cancer (NCT06382129, NCT06382116), Triple-Negative Breast Cancer (NCT06382142), HR+HER2- Breast Cancer (NCT06343948)	Cancer	Sichuan Baili Pharmaceutical Co. Ltd., Systimmune	Bristol Myers Squibb
BL-M07D1		HER2	Full length Ab conjugate	Monospecific	TBD	IgG1	kappa	ADC	Undisclosed	Topoisomerase I inhibitor, Ed-04	TBD	Phase 3	Breast cancer (NCT06316531 /CTR20240858)	Cancer	Sichuan Baili Pharmaceutical Co. Ltd., Systimmune
BMS-986012, MDX1110		Fucosyl-GM1	Full length Ab	Monospecific	Human	IgG1	TBD	Unconjugated			Afucosylated (improve FcγRIIIa binding/improve ADCC)	Phase 3 pending	Small cell lung cancer (NCT06646276)	Cancer	Bristol Myers Squibb
BNT316, ONC-392	Gotistobart	CTLA-4	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			M252Y, S254T, T256E (half-life extension); S298A, E333A, K334A (enhanced ADCC)	Phase 3	Non-small cell lung cancer (NCT05671510)	Cancer	OncoC4 Inc.	BioNTech SE
CAEL-101, Ch mAb 11-1F4	Anselamimab	Amyloid light chain	Full length Ab	Monospecific	Chimeric	IgG1	kappa	Unconjugated			None found	Phase 3	Light chain (AL) amyloidosis (NCT04512235, NCT04504825)	Immune-mediated / inflammatory disorders	AstraZeneca
CBP-201	Rademikibart	IL-4R alpha	Full length Ab	Monospecific	Human	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 3	Atopic dermatitis (CTR20242160 / NCT06477835), Asthma (CTR20242195 / NCT06488755)	Immune-mediated / inflammatory disorders	Suzhou Connect Biopharmaceuticals Ltd.	Simcere Pharmaceutical Co. Ltd
CC-93538, RPC4046; ABT-308, 13C5.5	Cendakimab	IL-13	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			L234A, L235A (impair Fc effector functions)	Phase 3	Eosinophilic gastroenteritis (NCT05214768); Eosinophilic esophagitis (NCT04753697, NCT04991935)	Immune-mediated / inflammatory disorders	AbbVie	Bristol Myers Squibb
CDP-7657	Dapirolizumab pegol	CD40L	Fragment conjugate - Fab, pegylated	Monospecific	Humanized	NA	kappa	Immunoconjugate, Pegylated		PEG	None found	Phase 3	Systemic lupus erythematosus (NCT04976322, NCT04294667, NCT06617325 not yet recruiting)	Immune-mediated / inflammatory disorders	UCB Biopharma	Biogen
CDX-0159	Barzolvolimab	c-Kit	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			L234A, L235Q, K322Q (reduced effector function), M252Y, S254T, T256E (half life extension)	Phase 3	Chronic Spontaneous Urticaria (NCT06455202, NCT06445023)	Immune-mediated / inflammatory disorders	Celldex
COR-001, WBP216 , MEDI5117	Ziltivekimab	IL-6	Full length Ab	Monospecific	Human	IgG1	kappa	Unconjugated			M252Y, S254T, T256E (half life extension)	Phase 3	Atherosclerotic cardiovascular disease, chronic kidney disease (NCT05021835, NCT06118281); Heart Failure (NCT05636176, NCT06200207); Atherosclerosis and inflammation (NCT06263244 not yet recuiting)	Cardiovascular / hemostasis disorders	AstraZeneca	Novo Nordisk
CS1003	Nofazinlimab	PD-1	Full length Ab	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 3	Hepatocellular carcinoma (NCT04194775)	Cancer	Cstone Pharma	EQRx
CSL300, ALD518; BMS-945429	Clazakizumab	IL-6	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			N297A (Fc-aglycosylated)	Phase 3	Atherosclerotic Cardiovascular Disease, End-stage kidney disease (NCT05485961)	Immune-mediated / inflammatory disorders	H. Lundbeck A/S	Vitaeris
DB-1303, BNT323		HER2	Full length Ab conjugate	Monospecific	TBD	IgG1	TBD	ADC	Enzymatically cleavable peptide linker	Topoisomerase I inhibitor, P1003	TBD	Phase 3	Breast cancer (NCT06265428, NCT06018337); Endometrial cancer (NCT06340568 not yet recruiting)	Cancer	Duality Biologics (Suzhou) Co. Ltd.	BioNTech SE
DP303c		HER2	Full length Ab conjugate	Monospecific	Humanized	IgG1	kappa	ADC	Cleavable linker	Tubulin inhibitor, Monomethyl auristatin E (MMAE)	None found	Phase 3	Breast cancer (NCT05901935)	Cancer	CSPC Pharmaceutical Group Limited
DS-6000A	Raludotatug deruxtecan	Cadherin-6	Full length Ab conjugate	Monospecific	Humanized	IgG1	kappa	ADC	Glycine-Glycine-Phenylalanine-Glycine (GGFG; Cleavable linker)	Topoisomerase I inhibitor, DXd/DX-8951 (MAAA-1181a)	None found	Phase 2/3	Ovarian cancer (NCT06161025)	Cancer	Daiichi Sankyo Co. Ltd	Merck
DS-7300a	Ifinatamab deruxtecan	B7-H3	Full length Ab conjugate	Monospecific	Humanized	IgG1	kappa	ADC	Glycine-Glycine-Phenylalanine-Glycine (GGFG; Tetrapeptide-based cleavable linker)	Topoisomerase I inhibitor, DXd/DX-8951 (MAAA-1181a)	None found	Phase 3	Small cell lung cancer (NCT06236438), Esophageal Squamous Cell Carcinoma (NCT06644781 not yet recruiting)	Cancer	Daiichi Sankyo Co. Ltd	Merck Sharp & Dohme
E2814	Etalanetug	Tau (MTBR)	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			None found	Phase 2/3	Dominantly inherited Alzheimer's Disease (NCT05269394, NCT01760005)	Neurological disorders	Eisai Inc.	University College London
EB05, NI-0101	Paridiprubart	TLR4	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			N325S, L328F (abrogates C1q and FcγRIII binding, increases FcγRII binding, retains FcγRI high affinity binding)	Phase 2/3	COVID-19-related acute respiratory distress syndrome (NCT04401475)	Immune-mediated / inflammatory disorders	NovImmune SA	Edesa Biotech, Genentech
ES102, INBRX-106		OX40	Fragment-Fc - (VHH-VHH-VHH)2-Fc	Monospecific	Humanized	TBD	NA	Unconjugated			None found	Phase 2/3	Head and neck cancer (NCT06295731)	Cancer	Inhibrx Biosciences Inc.	Elpiscience Biopharma Ltd.
ES104, CTX-009, TR009, NOV1501, ABL001		DLL4, VEGF-A	Appended Ig - scFv-scFv-Full-length antibody	Bispecific	TBD	TBD	TBD	Unconjugated			TBD	Phase 2/3	Biliary tract cancers (NCT05506943)	Cancer	National OncoVenture	Compass Therapeutics Inc., Elpiscience Biopharmaceuticals, ABL Bio Inc.
ESG401, ESG-401, STI-3258		TROP-2	Full length Ab conjugate	Monospecific	Humanized	TBD	TBD	ADC	Undisclosed	Topoisomerase I inhibitor, SN38 (irinotecan active metabolite)	TBD	Phase 3	Metastatic Breast Cancer (NCT06383767)	Cancer	Sorrento Therapeutics Inc.	Escugen Biotechnology Co Ltd., Levena (Suzhou) Biopharma Co. Ltd.
MK-3000, EYE103, F4L5.13, ANT-39, Restoret™		FZD4, LRP5, LRP5	Fragment-Fc - 1+1 asymmetric, Diabody-Fc-Diabody	Multispecific, Trispecific	TBD	TBD	TBD	Unconjugated			None found	Phase 2/3	Diabetic macular edema and neovascular age-related macular degeneration (NCT06571045)	Ophthalmic disorders	AntlerA Therapeutics	Merck
F520	Rulonilimab	PD-1	Full length Ab	Monospecific	Chimeric	IgG1	kappa	Unconjugated			N297A (Fc-aglycosylated); T250Q, M428L (half life extension)	Phase 2/3	Hepatocellular carcinoma (NCT05408221)	Cancer	Shandong New Time Pharmaceutical Co. LTD
FDA018, FDA018-ADC		TROP-2	TBD	Monospecific	TBD	TBD	TBD	ADC	Undisclosed	Topoisomerase I inhibitor, SN38 (irinotecan active metabolite)	TBD	Phase 3	Triple-negative Breast Cancer (NCT06519370 / CTR20242630)	Cancer	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd
FG-M108, M108		Claudin-18.2	Full length Ab	Monospecific	TBD	IgG1	TBD	Unconjugated			TBD	Phase 3	Gastric or gastroesophageal junction adenocarcinoma (NCT06177041)	Cancer	FutureGen Biopharmaceutical (Beijing) Co. Ltd
FPA144	Bemarituzumab	FGFR2b	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			Afucosylated (improve FcγRIIIa binding/improve ADCC)	Phase 3	Gastric cancer/gastroesophageal junction adenocarcinoma (NCT05111626, NCT05052801)	Cancer	Amgen	Zai Lab
FUB523, BION-1301	Zigakibart	APRIL	Full length Ab	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 3	IgA nephropathy (NCT05852938)	Immune-mediated / inflammatory disorders	Novartis Pharmaceuticals
GEN1046, DuoBody-PD-L1x4, BNT311	Acasunlimab	PD-L1, 4-1BB	Full length Ab - Duobody	Bispecific	Humanized	IgG1	kappa/lambda	Unconjugated			L234F, L235E, D265A (reduced effector function), F405L or K409R (heterodimerization, cFAE)	Phase 3	Non-Small Cell Lung Cancer (NCT06635824)	Cancer	Genmab
GMA-102 (diabetes indication), GMA-105 (obesity indication), Glutazumab (not WHO assigned INN)	Gulgafafusp alfa	GLP-1R	Full length Ab fusion	Monospecific	Humanized	IgG2	TBD	Immunoconjugate		GLP-1 peptide	None found	Phase 3	Type 2 diabetes (CTR20222558, CTR20211661)	Metabolic disorders	Gmax Biopharm Australia Pty Ltd
GR1801	Silevimig	Rabies virus (glycoprotein)	Fragment-Fc - scFv-Fc-Fab	Bispecific	Human	IgG1	TBD	Unconjugated			None found	Phase 3	Rabies (NCT05846568)	Infectious diseases	Genrix (Shanghai) Biopharmaceutical Co. Ltd.
GR1802, GR-1802		IL-4R alpha	Full length Ab	Monospecific	TBD	IgG1	kappa	Unconjugated			TBD	Phase 3	Atopic dermatitis (NCT06216392 / CTR20233857), Chronic Rhinosinusitis With Nasal Polyps (NCT06516302)	Immune-mediated / inflammatory disorders	Genrix (Shanghai) Biopharmaceutical Co. Ltd.
GSK3511294	Depemokimab	IL-5	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			M252Y, S254T, T256E (half-life extension)	Phase 3	Hypereosinophilic syndrome (NCT05334368); Eosinophilic granulomatosis with polyangiitis (NCT05263934); Nasal polyps (NCT05274750, NCT05281523); Severe uncontrolled asthma with an eosinophilic phenotype (NCT05243680, NCT04719832, NCT04718103, NCT04718389)	Immune-mediated / inflammatory disorders	GSK
GSK4069889, TSR-022	Cobolimab	TIM3	Full length Ab	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 2/3	Non-small cell lung cancer (NCT04655976)	Cancer	GSK
GSK4428859, EOS884448, EOS-448, RCA-2	Belrestotug	TIGIT	Full length Ab	Monospecific	Human	IgG1	kappa	Unconjugated			None found	Phase 3	Non-small cell lung cancer (NCT06472076)	Cancer	iTEOS Therapeutics	GSK
GSK4527226, AL001	Latozinemab	Sortilin	Full length Ab	Monospecific	Human	IgG1	kappa	Unconjugated			L234A, L235A, P331S (remove Fc effector functions)	Phase 3	Frontotemporal dementia (NCT04374136)	Neurological disorders	Alector Inc.	GSK
HB0017		IL-17A	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			TBD	Phase 3	Plaque psoriasis (CTR20240521 / NCT06477237)	Immune-mediated / inflammatory disorders	Huabo Biopharm Co. Ltd.
HB0034		IL-36R	TBD	Monospecific	Humanized	TBD	TBD	Unconjugated			TBD	Phase 2/3	Generalized pustular psoriasis (NCT06477536)	Immune-mediated / inflammatory disorders	Shanghai Huaota Biopharmaceutical Co. Ltd.
HLX22, AC-101		HER2	TBD	Monospecific	Humanized	TBD	TBD	Unconjugated			TBD	Phase 3	Gastric cancer (CTR20243366 / NCT06532006)	Cancer	Alligator Bioscience AB	Shanghai Henlius Biotech Co. Ltd., AbClon Inc.
HS-20093, GSK5764227		B7-H3	Full length Ab	Monospecific	Humanized	IgG1	TBD	ADC	Undisclosed	Topoisomerase I inhibitor	TBD	Phase 3	Small cell lung cancer (NCT06498479, CTR20242440 / NCT06526624 not yet recruiting)	Cancer	Shanghai Hansoh Biomedical Co. Ltd	GSK
I-131-BC8	Apamistamab-Iodine (131I)	CD45	Full length Ab conjugate	Monospecific	Murine	IgG1	kappa	RIC		I-131	None found	Phase 3	Acute myeloid leukemia (NCT02665065)	Cancer	Actinium Pharmaceuticals	Immedica AB
IAH0968		HER2	Full length Ab	Monospecific	TBD	TBD	TBD	Unconjugated			Afucosylated (improve FcγRIIIa binding/improve ADCC)	Phase 2/3	Colorectal Cancer (NCT05673512), Gastric cancer (NCT06504732 not yet recruiting)	Cancer	SUNHO (China) BioPharmaceutical Co. Ltd., Beijing Sunho Pharmaceutical Co.
IBI343		Claudin-18.2	Full length Ab conjugate	Monospecific	TBD	TBD	TBD	ADC	Undisclosed	Topoisomerase I inhibitor, Exatecan	TBD	Phase 3	Gastric or gastroesophageal junction adenocarcinoma (NCT06238843 enrolling by invitation)	Cancer	Innovent Biologics (Suzhou) Co. Ltd.
IKS014, LCB14-0110, FS-1502	Caxmotabart entudotin	HER2	Full length Ab conjugate	Monospecific	Humanized	IgG1	kappa	ADC	β-glucuronidase (BG) Cleavable linker	Tubulin inhibitor, Monomethyl auristatin F (MMAF)	None found	Phase 3	Breast Cancer (CTR20230426 / NCT05755048)	Cancer	LegoChem Biosciences Inc.	IKSUDA Therapeutics, Shanghai Fosun Pharmaceutical Development Co Ltd.
IMC-F106C		PRAME, CD3	Fragment fusion - scFv-TCR	Bispecific	TBD	NA	TBD	Immunoconjugate		T cell receptor	NA	Phase 3	Melanoma (NCT06112314)	Cancer	Immunocore Ltd
IMGN632	Pivekimab sunirine	CD123	Full length Ab conjugate	Monospecific	Humanized	IgG1	kappa	ADC	Alanine-Alanine (Cleavable linker)	DNA binding, DGN549 IGN (indolino-benzodiazepine)	S442C (site-specific conjugation)	Phase 2 pivotal	Blastic plasmacytoid dendritic cell neoplasm (NCT03386513 CADENZA)	Cancer	ImmunoGen
JCT205, INBRX-109	Ozekibart	DR5	Fragment-Fc - (VHH-VHH)2-Fc	Monospecific	Humanized	IgG1	NA	Unconjugated			E233>del,L234>del, L235>del (reduced effector function: CDC and ADCC)	Phase 2 pivotal	Conventional Chondrosarcoma (NCT04950075)	Cancer	Inhibrx Biosciences Inc.	Transcenta Holding Limited
JMT101	Becotatug	EGFR	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			None found	Phase 2 pivotal	Non-small cell lung cancer (CTR20212469, NCT06319313 / CTR20240822, NCT06380348 / CTR20241252)	Cancer	CSPC Pharmaceutical Group Limited
JNJ-63723283	Cetrelimab	PD-1	Full length Ab	Monospecific	Human	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 3	Bladder cancer (NCT04658862, NCT05714202)	Cancer	Janssen Research & Development LLC	Xoma
JS004, TAB004	Tifcemalimab	BTLA	Full length Ab	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge stabilization)	Phase 3	Small cell lung cancer (NCT06095583 / CTR20233182), Hodgkin Lymphoma (NCT06170489 / CTR20234002)	Cancer	Shanghai Junshi Bioscience Co Ltd
JS005	Roconkibart	IL-17A	Full length Ab	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge stabilization)	Phase 3	Plaque Psoriasis (NCT05975268)	Immune-mediated / inflammatory disorders	Shanghai Junshi Bioscience Co Ltd
JSKN003, JSKN033 (combo of JSKN003 and envafolimab)		HER2, HER2	Full length Ab conjugate	Bispecific, Biparatopic	Humanized	TBD	TBD	ADC	Undisclosed	Topoisomerase I inhibitor	TBD	Phase 3	Breast cancer (NCT06079983)	Cancer	Alphamab (Australia) Co Pty Ltd.
KHK4083, AMG451	Rocatinlimab	OX40	Full length Ab	Monospecific	Human	IgG1	kappa	Unconjugated			None found	Phase 3	Atopic dermatitis (NCT05398445, NCT05633355, NCT05651711, NCT05724199, NCT05704738, NCT05882877, NCT05899816, NCT06224192), Prurigo Nodularis (NCT06527404)	Immune-mediated / inflammatory disorders	Kyowa Hakko Kirin	Amgen
Kintuximab, gentuximab, cintuximab (not WHO assigned INN)		VEGFR2	Full length Ab	Monospecific	Chimeric	TBD	TBD	Unconjugated			TBD	Phase 3	Advanced gastric or gastroesophageal junction adenocarcinoma (NCT05919381 / CTR20220815)	Cancer	GeneScience Pharmaceuticals Co. Ltd.	Changchun Jinsai Pharmaceutical Co. Ltd.
KN026	Anbenitamab	HER2, HER2	Full length Ab	Bispecific, Biparatopic	Humanized	IgG1	kappa	Unconjugated			Hetero HH, HL-pairing: cL: S354C-T366W-K409A x Y349C-T366S-L368A-F405K-Y407V (bispecific assembly)	Phase 3	Gastric (NCT05427383), breast cancer (NCT05838066)	Cancer	Jiangsu Alphamab Biopharmaceuticals Co. Ltd	Sanofi
KN046	Erfonrilimab	PD-L1, CTLA-4	Fragment-Fc - 2+2 symmetric, (VHH-VHH')2-Fc, Tandem-VHH-Fc	Bispecific	Chimeric, Humanized	IgG1	NA	Unconjugated			Hetero HH, HL-pairing: cL: S354C-T366W-K409A x Y349C-T366S-L368A-F405K-Y407V (bispecific assembly)	Phase 3	Non-small-cell lung cancer (NCT04474119), Advanced Pancreatic Ductal Adenocarcinoma (NCT05149326)	Cancer	Alphamab (Australia) Co Pty Ltd.	Pfizer, Zelgen, Sunny Lake, Kintor, Sinovent, InxMed
KSI-301, OG1953	Tarcocimab tedromer	VEGF-A	Full length Ab conjugate - ABC	Monospecific	Humanized	IgG1	kappa	Immunoconjugate		Biopolymer	L234A, L235A, G237A (impair Fc effector functions), L443C (Cys for site specific conjugation)	Phase 3	Non-proliferative Diabetic Retinopathy (NCT06270836), Wet Age-related Macular Degeneration (NCT06556368)	Ophthalmic disorders	Kodiak Sciences Inc
L19-TNF, L19TNF, L19(scFv)2-TNF	Onfekafusp alfa	Fibronectin EDB, TNF	Fragment fusion - scFv-TNF	Monospecific	Human	NA	TBD	Immunoconjugate - Immunocytokine		TNF	NA	Phase 3	Soft tissue sarcoma (NCT04650984)	Cancer	Philogen S.p.A.	Sun Pharma, Merck Sharp & Dohme
LMN-201		C. difficile (exotoxin TcdB)	Fragment - sdAb, VHH dimers	Mixture of 3 monospecific antibodies	TBD	NA	NA	Unconjugated			NA	Phase 2/3	Clostridioides Difficile Infection (NCT05330182)	Infectious diseases	Lumen Bioscience Inc.
LY3372993	Remternetug	Amyloid beta (N3pG)	Full length Ab	Monospecific	Human	IgG1	kappa	Unconjugated			None found	Phase 3	Alzheimer's Disease (NCT05463731, NCT06653153 not yet recruiting)	Neurological disorders	Eli Lilly and Company
M1095, MSB0010841, ALX-0761	Sonelokimab	IL-17A, IL17F, Albumin	Fragment - sdAb, VHH-VHH'-VHH	Multispecific, Trispecific	Humanized	NA	NA	Unconjugated			NA	Phase 3	Hidradenitis Suppurativa (NCT06411899, NCT06411379), Psoriatic arthritis (NCT06641076 not yet recruiting, NCT06641089 not yet recruiting)	Immune-mediated / inflammatory disorders	Merck Serono	MoonLake Immunotherapeutics AG, Bond Avillion 2 Development LP
M701		EpCAM, CD3	Fragment-Fc - YBODY	Bispecific	Chimeric	TBD	TBD	Unconjugated			TBD	Phase 3	Malignant ascities (NCT06432296)	Cancer	Wuhan YZY Biopharma Co. Ltd.
MAA868, NOV-12	Abelacimab	Factor XI	Full length Ab	Monospecific	Human	IgG1	lambda	Unconjugated			D265A P329A. Reduced effector functions	Phase 3	Venous thromboembolism (NCT05171075, NCT05171049), Atrial Fibrillation (NCT05712200)	Cardiovascular / hemostasis disorders	Novartis Pharmaceuticals	Anthos Therapeutics, MorphoSys
SYSA1801		Claudin-18.2	Full length Ab	Monospecific	Human	IgG1	TBD	ADC	Valine-Citrulline (Cleavable linker)	Tubulin inhibitor, Monomethyl auristatin E (MMAE)	None found	Phase 3 pending	CTR20244240 (gastric or gastroesophageal junction adenocarcinoma not yet recruiting)	Cancer	CSPC Pharmaceutical Group Limited	Elevation Oncology Inc.
MCLA-158	Petosemtamab	EGFR, LGR5	Full length Ab - Biclonic	Bispecific	Human	IgG1	kappa	Unconjugated			Low fucose; L351D, L368E x L351K, T366K (heterodimerization)	Phase 3	Head and neck cancer (NCT06496178, NCT06525220)	Cancer	Merus B.V.
MEDI3506	Tozorakimab	IL-33	Full length Ab	Monospecific	Human	IgG1	lambda	Unconjugated			None found	Phase 3	Chronic obstructive pulmonary disease (NCT05166889, NCT05158387, NCT05742802, NCT06040086); Acute respiratory failure (NCT05624450)	Respiratory diseases	AstraZeneca
MEDI5752	Volrustomig	CTLA-4, PD-1	Full length Ab	Bispecific	Human	IgG1	kappa/lambda	Unconjugated			Reduced effector functions	Phase 3	Cervical cancer (NCT06079671); Non-small cell lung cancer (NCT05984277), Head and Neck Squamous Cell Carcinoma (NCT06129864), Pleural Mesothelioma (NCT06097728)	Cancer	AstraZeneca
MEDI9447	Oleclumab	CD73	Full length Ab	Monospecific	Human	IgG1	lambda	Unconjugated			L234F, L235E, P331S (reduced effector function)	Phase 3	Non-small cell lung cancer (NCT05221840)	Cancer	AstraZeneca
MG-K10, BC005	Comekibart	IL-4R alpha	Full length Ab	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge stabilization), M428L, N434S (half life increase)	Phase 3	Atopic Dermatitis (CTR20232813 / NCT06026891)	Immune-mediated / inflammatory disorders	Shanghai Meiji Biotechnology Co Ltd
MIL62		CD20	Full length Ab	Monospecific	Humanized	TBD	TBD	Unconjugated			Afucosylated (improve FcγRIIIa binding/improve ADCC)	Phase 3	Neuromyelitis optica spectrum disorder (NCT05314010); Follicular lymphoma and marginal zone lymphoma (NCT04834024); Systemic Lupus Erythematosus (NCT05796206); Primary Membranous Nephropathy (NCT05862233)	Cancer	Beijing Mabworks Biotech Co. Ltd.
MK-1308, AK107	Quavonlimab	CTLA-4	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			None found	Phase 3	Renal cell carcinoma (NCT04736706, NCT05899049)	Cancer	Akeso Inc.	Merck
MK-4280	Favezelimab	LAG-3	Full length Ab	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 3	Hodgkin lymphoma (NCT05508867); Colorectal cancer (NCT05600309, NCT05064059)	Cancer	Merck Sharp & Dohme Corp
MK-7684	Vibostolimab	TIGIT	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			None found	Phase 3	Non-small cell lung cancer (NCT04738487; NCT05298423; NCT05226598); Small cell lung cancer (NCT05224141); Melanoma (NCT05665595)	Cancer	Merck Sharp & Dohme Corp.
MRG002		HER2	Full length Ab conjugate	Monospecific	Humanized	IgG1	TBD	ADC	Valine-Citrulline (Cleavable linker)	Tubulin inhibitor, Monomethyl auristatin E (MMAE)	Hyperfucosylated (reduce Fc𝛾RIIIa binding/reduce ADCC)	Phase 3	Breast Cancer (NCT04924699), Urothelium Cancer (NCT05754853)	Cancer	LEPU Biopharma, Shanghai Miracogen Inc.
MTIG7192A, RO7092284, RG6058	Tiragolumab	TIGIT	Full length Ab	Monospecific	Human	IgG1	kappa	Unconjugated			None found	Phase 3	Non-small cell lung cancer (NCT04294810, NCT04513925, NCT04619797, NCT06267001); Esophageal cancer (NCT04543617, NCT04540211), Small Cell Lung Carcinoma (NCT04665856, NCT04256421), Hepatocellular carcinoma (NCT05904886)	Cancer	Genentech
NEOD001; murine parent is 2A4	Birtamimab	Amyloid light chain	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			None found	Phase 3	Light chain (AL) amyloidosis (NCT04973137)	Cardiovascular / hemostasis disorders	Onclave Therapeutics Limited	Prothena
NN-7769, NNC0365-3769, Mim8	Denecimig	Factor IXa, Factor X	Full length Ab - Duobody	Bispecific	Human	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 3	Hemophilia A with or without inhibitors (NCT05306418, NCT05053139, NCT05685238, NCT05878938)	Cardiovascular / hemostasis disorders	Novo Nordisk	Genmab
NN8765, IPH-2201, NNC141-0100	Monalizumab	NKG2A	Full length Ab	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 3	Squamous Cell Carcinoma of the Head and Neck (NCT04590963); Non-small Cell Lung Cancer (NCT05221840)	Cancer	Novo Nordisk	AstraZeneca, Innate Pharma
PF-06801591	Sasanlimab	PD-1	Full length Ab	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 3	Non-muscle invasive bladder cancer (NCT04165317)	Cancer	Pfizer
PF-06823859, PF06823859	Dazukibart	IFN beta	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			L234A, L235A, G237A (impair Fc effector functions)	Phase 3	Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)] (NCT05895786, NCT06698796 not yet recruiting)	Immune-mediated / inflammatory disorders	Pfizer
PF-07940370, RO4905417, RG1512	Inclacumab	P-selectin	Full length Ab	Monospecific	Human	IgG4	kappa	Unconjugated			S228P (hinge-stabilization); L235E (impair Fc effector function)	Phase 3	Vaso-occlusive crisis in sickle cell disease patients (NCT05348915, NCT04935879)	Cardiovascular / hemostasis disorders	Hoffmann-La Roche	Pfizer
PM8002, BNT327		PD-L1, VEGF A	Appended Ig - VHH-IgG	Bispecific	TBD	IgG1	TBD	Unconjugated			Fc silencing mutations (specific ones unknown); anti-PDL1 VHH fused to the antibody to become bispecific	Phase 2/3	Non-small Cell Lung Cancer (NCT05756972); Small Cell Lung Cancer (NCT05844150, NCT06616532 not yet recruiting), Triple negative breast cancer (NCT06419621)	Cancer	Biotheus Inc.	BioNTech
PRA023, MK-7240	Tulisokibart	TL1a	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			L234A, L235A, P329A (impair Fc effector functions)	Phase 3	Ulcerative colitis (NCT06052059), Crohn's Disease (NCT06430801), Crohn's Disease and Ulcerative colitis (NCT06651281 not yet recruiting)	Immune-mediated / inflammatory disorders	Merck Sharp & Dohme LLC
QX002N		IL-17A	Full length Ab	Monospecific	Humanized	IgG1	TBD	Unconjugated			TBD	Phase 3	Ankylosing spondylitis (CTR20232574)	Immune-mediated / inflammatory disorders	Jiangsu Qyuns Therapeutics Co. Ltd.
QX005N, SNC005		IL-4R alpha	Full length Ab	Monospecific	TBD	TBD	TBD	Unconjugated			TBD	Phase 3	Atopic dermatitis (CTR20241068), Nodular prurigo (CTR20241660)	Immune-mediated / inflammatory disorders	Jiangsu Qyuns Therapeutics Co. Ltd.
REGN2477	Garetosmab	Activin A	Full length Ab	Monospecific	Human	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 3	Fibrodysplasia ossificans progressiva (NCT05394116)	Skeletal disorders	Regeneron Pharmaceuticals
REGN3500, SAR440340	Itepekimab	IL-33	Full length Ab	Monospecific	Human	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 3	Chronic obstructive pulmonary disease (NCT04751487, NCT04701983, NCT06208306)	Respiratory diseases	Regeneron Pharmaceuticals
REGN3767	Fianlimab	LAG-3	Full length Ab	Monospecific	Human	IgG4	kappa	Unconjugated			S228P (hinge-stabilization); E233P, F234V, L235A, G236del (reduced effector function)	Phase 3	Melanoma (NCT05352672, NCT05608291, NCT06190951, NCT06246916); Non-small Cell Lung Cancer (NCT05785767, NCT05800015)	Cancer	Regeneron Pharmaceuticals	Sanofi
REGN4461	Mibavademab	LEPR	Full length Ab	Monospecific	Human	IgG4	kappa	Unconjugated			S228P (hinge stabilization)	Phase 3 pending	Generalized Lipodystrophy (NCT06548100)	Metabolic disorders	Regeneron Pharmaceuticals
REGN5713-5714-5715	Atisnolerbart, bremzalerbart, umesolerbart	Bet v 1	Full length Ab	Mixture of 3 monospecific antibodies	Human	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 3	Seasonal allergic rhinitis (NCT04709575)	Immune-mediated / inflammatory disorders	Regeneron Pharmaceuticals
RO5509554, RG7155	Emactuzumab	CSF-1R	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			None found	Phase 3	Tenosynovial giant cell tumor (NCT05417789)	Cancer	Hoffmann-La Roche	SynOx Therapeutics
RO7187807, MSTT1041A, RG6149, AMG282	Astegolimab	IL-33R	Full length Ab	Monospecific	Human	IgG2	kappa	Unconjugated			None found	Phase 3	Chronic obstructive pulmonary disease (NCT05595642, NCT05878769)	Immune-mediated / inflammatory disorders	Amgen	Genentech
RO7200220, RG6179, EBI-031	Vamikibart	IL-6	Full length Ab	Monospecific	Humanized	IgG2	kappa	Unconjugated			H310A (half life extension)	Phase 3	Uveitic macular edema (NCT05642325, NCT05642312)	Ophthalmic disorders	Sesen Bio	Hoffmann-La Roche
RO7204239, GYM329, RG6237		Myostatin	Full length Ab	Monospecific	TBD	TBD	TBD	Unconjugated			Specific mutations not found; engineered for selective and enhanced binding to the human FcγRIIb and for stronger affinity to FcRn in acidic pH conditions	Phase 2/3	Spinal muscular atrophy (NCT05115110)	Neurological disorders	Chugai Pharmaceutical Co. Ltd.
RVT-3101, PF-06480605, RG6631, RO7790121	Afimkibart	TL1a	Full length Ab	Monospecific	Human	IgG1	kappa	Unconjugated			L234A, L235A, G237A (impair Fc effector functions)	Phase 3	Crohn Disease, Ulcerative colitis (NCT06588855, NCT06589986)	Immune-mediated / inflammatory disorders	Pfizer	Hoffmann-La Roche, Roivant Sciences
RZ358, XOMA 358, XMetD	Ersodetug	Insulin receptor	Full length Ab	Monospecific	Human	IgG2	kappa	Unconjugated			None found	Phase 3	Congenital hyperinsulinism (NCT06208215)	Metabolic disorders	XOMA	Rezolute Inc
SAR441344, INX-021	Frexalimab	CD40L	Full length Ab	Monospecific	Chimeric	IgG1	kappa	Unconjugated			V215A E269R K322A (enhanced effector functions)	Phase 3	Multiple sclerosis (NCT06141473, NCT06141486)	Immune-mediated / inflammatory disorders	ImmuNext	Sanofi
SAR445088, BIVV020	Riliprubart	Complement C1s	Full length Ab	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge-stabilization); L235E (impair Fc effector function)	Phase 3	Inflammatory Demyelinating Polyneuropathy (NCT06290128, NCT06290141)	Immune-mediated / inflammatory disorders	Sanofi
SAR445229, KY1005	Amlitelimab	OX40L	Full length Ab	Monospecific	Human	IgG4	kappa	Unconjugated			S228P (hinge stabilization); L235E ( reduce effector function); M428L, N434S (Half life extension)	Phase 3	Atopic dermatitis (NCT05492578, NCT06130566, NCT06407934, NCT06181435, NCT06224348, NCT06241118)	Immune-mediated / inflammatory disorders	Sanofi
SG301, SG301SC		CD38	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			TBD	Phase 3	Multiple Myeloma (NCT06508983 / CTR20241042)	Cancer	Hangzhou Sumgen Biotech Co. Ltd.
SGN-B6A	Sigvotatug vedotin	Integrin beta-6	Full length Ab conjugate	Monospecific	Humanized	IgG1	kappa	ADC	Valine-Citrulline (Cleavable linker)	Tubulin inhibitor, Monomethyl auristatin E (MMAE)	None found	Phase 3	Non-small cell lung cancer (NCT06012435)	Cancer	Seagen Inc.
SHR-1703		IL-5	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			M252Y, S254T, T256E (half life extension)	Phase 3 pending	Eosinophilic Asthma (NCT06653322), Eosinophilic Granulomatosis With Polyangiitis (NCT05979051)	Immune-mediated / inflammatory disorders	Jiangsu HengRui Medicine Co. Ltd.	Atridia Pty Ltd.
SHR-1819	Drotokibart	IL-4R alpha	Full length Ab	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge stabilization)	Phase 2/3	Atopic Dermatitis (NCT06468956 not yet recruiting), Prurigo Nodularis (NCT06554509)	Immune-mediated / inflammatory disorders	Shanghai Hengrui Pharmaceutical Co. Ltd.	Atridia Pty Ltd.
SHR-8068		CTLA-4	TBD	Monospecific	Human	TBD	TBD	Unconjugated			TBD	Phase 3 pending	Non-squamous Non-small cell lung cancer (NCT06335355), Hepatocellular carcinoma (NCT06618664 / CTR20243670)	Cancer	Hengrui Pharmaceutical	Suzhou Suncadia Biopharmaceuticals Co. Ltd.
SHR-A1904		Claudin-18.2	Full length Ab	Monospecific	Humanized	IgG1	TBD	ADC	Cleavable linker	Topoisomerase I inhibitor	TBD	Phase 3 pending	Gastric or Gastroesophageal Junction Adenocarcinoma (NCT06649292 not yet recruiting)	Cancer	Shanghai Hengrui Pharmaceutical Co. Ltd.	Merck KGaA
SHR-A1921		TROP-2	Full length Ab conjugate	Monospecific	TBD	IgG1	kappa	ADC	Undisclosed	Topoisomerase I inhibitor, SHR9265	TBD	Phase 2/3 and Phase 3 pending	Ovarian cancer (NCT06211023 / CTR20240254, NCT06394492)	Cancer	Shanghai Hengrui Pharmaceutical Co. Ltd.	Suzhou Suncadia Biopharmaceuticals Co. Ltd., Atridia Pty Ltd.
SHR-A2009		HER3	Full length Ab	Monospecific	Human	IgG1	TBD	ADC	Cleavable linker	Topoisomerase I inhibitor	TBD	Phase 3 pending	Non-small cell lung cancer (NCT06671379 / CTR20244118)	Cancer	Jiangsu HengRui Medicine Co. Ltd.
SI-B001	Izalontamab	EGFR, HER3	Appended Ig - 2+2 symmetric, IgG-(scFv)2	Bispecific	Chimeric / Humanized	IgG1	kappa/lambda	Unconjugated			None found	Phase 2/3	Non-small cell lung cancer (NCT05020769, NCT05943795)	Cancer	Sichuan Biokin Pharmaceutical	SystImmune Inc., Sichuan Baili Pharmaceutical Co. Ltd
SRK-015	Apitegromab	Myostatin	Full length Ab	Monospecific	Human	IgG4	lambda	Unconjugated			S228P (hinge-stabilization)	Phase 3	Spinal muscular atrophy (NCT05156320, NCT05626855)	Muscular disorders	Scholar Rock
SSGJ-601, 601		VEGF-A	Full length Ab	Monospecific	Humanized	TBD	TBD	Unconjugated			TBD	Phase 3	Branch retinal vein occlusion (NCT05520177)	Ophthalmic disorders	Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd
SSGJ-610, 610		IL-5	Full length Ab	Monospecific	Humanized	TBD	TBD	Unconjugated			TBD	Phase 3	Asthma (NCT06323213 / CTR20241581)	Immune-mediated / inflammatory disorders	Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd	3SBio
SSGJ-611, 611		IL-4R alpha	Full length Ab	Monospecific	Humanized	IgG4	TBD	Unconjugated			TBD	Phase 3	Atopic dermatitis (NCT06173284, NCT06554847), Sinusitis with nasal polyps (NCT06639295 not yet recruiting)	Immune-mediated / inflammatory disorders	Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd	3SBio
SSGJ-613		IL-1 beta	TBD	Monospecific	Humanized	TBD	TBD	Unconjugated			TBD	Phase 3	Gouty arthritis (CTR20233982 / NCT06169891)	Immune-mediated / inflammatory disorders	Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd.	3SBio
STRO-002	Luveltamab tazevibulin	FR alpha	Full length Ab conjugate	Monospecific	Human	IgG1	kappa	ADC	Valine citrulline p-aminobenzyl carbamate linker functionalized with dibenzocyclooctyne (DBCO) (Cleavable linker)	Tubulin inhibitor, SC209 (Hemiasterlin)	Y180pAMF, F404pAMF (non-natural amino acid for site specific conjugation)	Phase 2/3	Ovarian Cancer, Fallopian Tube Cancer (NCT05870748)	Cancer	Sutro Biopharma	Tasly Biopharmaceuticals Co. Ltd.
TJ004309, TJ4309, TJD5	Uliledlimab	CD73	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			N297A (Fc-aglycosylated)	Phase 2/3	Non-small cell lung cancer (CTR20240650)	Cancer	TRACON Pharmaceuticals	I-Mab Biopharma
TJ202, MOR202, MOR03087	Felzartamab	CD38	Full length Ab	Monospecific	Human	IgG1	lambda	Unconjugated			None found	Phase 3	Antibody-mediated rejection (NCT06685757)	Cancer	MorphoSys AG	Human Immunology Biosciences Inc. (HIBio), I-Mab Biopharma
TLX591, ATL-101, Lu-177-huJ591, Rosopatamab-177Lu-DOTA	Rosopatamab tetraxetan 177Lu	PSMA	Full length Ab conjugate	Monospecific	Humanized	IgG1	kappa	RIC		Lu-177	None found	Phase 3	Prostate cancer (NCT04876651, NCT06520345)	Cancer	Telix Pharmaceuticals Ltd
TNM001		RSV (F glycoprotein)	Full length Ab	Monospecific	Human	TBD	TBD	Unconjugated			TBD	Phase 2/3	Preventing lower respiratory tract infections caused by respiratory syncytial virus in infants (NCT06083623)	Infectious diseases	Zhuhai Trinomab Biotechnology Co Ltd.
TPX-4589, LM-302		Claudin-18.2	Full length Ab conjugate	Monospecific	Humanized	IgG1	TBD	ADC	Valine-Alanine (Cleavable linker)	Tubulin inhibitor, Monomethyl auristatin E (MMAE)	TBD	Phase 3	Gastric or Gastroesophageal Junction Adenocarcinoma (NCT06351020)	Cancer	LaNova Medicines Zhejiang Co. Ltd.	Bristol Myers Squibb
TQH2722		IL-4R alpha	TBD	Monospecific	Human	TBD	TBD	Unconjugated			TBD	Phase 3	Atopic dermatitis (NCT06552520 / CTR20242940)	Immune-mediated / inflammatory disorders	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co. Ltd.
UX143, BPS804, MOR05813	Setrusumab	Sclerostin	Full length Ab	Monospecific	Human	IgG2	lambda	Unconjugated			None found	Phase 3	Osteogenesis imperfecta (NCT05125809, NCT05768854, NCT06636071)	Skeletal disorders	Mereo BioPharma Group plc	Ultragenyx Pharmaceutical Inc.
VAY736, NOV-5	Ianalumab	BAFFR	Full length Ab	Monospecific	Human	IgG1	kappa	Unconjugated			Afucosylated (improve FcγRIIIa binding/improve ADCC)	Phase 3	Sjogren syndrome (NCT05350072, NCT05349214, NCT05985915); Autoimmune hepatitis (NCT03217422); Lupus nephritis (NCT05126277); Systemic Lupus Erythematosus (NCT05624749, NCT05639114, NCT06133972); Warm Autoimmune Hemolytic Anemia (wAIHA) (NCT05648968); Primary Immune Thrombocytopenia (ITP) (NCT05653349, NCT05653219)	Immune-mediated / inflammatory disorders	Novartis Pharmaceuticals
VIS649	Sibeprenlimab	APRIL	Full length Ab	Monospecific	Humanized	IgG2	kappa	Unconjugated			None found	Phase 3	IgA nephropathy (NCT05248646; NCT05248659)	Immune-mediated / inflammatory disorders	Otsuka Pharmaceutical Development & Commercialization Inc.
VLS-101, MK-2140	Zilovertamab vedotin	ROR1	Full length Ab conjugate	Monospecific	Humanized	IgG1	kappa	ADC	Valine-citrulline (Maleimidocaproyl-valine-citrulline-para-aminobenzoate; Cleavable linker)	Tubulin inhibitor, Monomethyl auristatin E (MMAE)	None found	Phase 2/3	Diffuse large B-cell lymphoma (NCT05139017)	Cancer	Merck Sharp & Dohme LLC
VRDN-003		IGF-1R	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			M252Y, S254T, T256E (half-life extension)	Phase 3	Thyroid eye disease (NCT06625398, NCT06625411)	Immune-mediated / inflammatory disorders	Viridian Therapeutics Inc.
VYD222	Pemivibart	SARS-CoV-2 (spike protein)	Full length Ab	Monospecific	Human	IgG1	lambda	Unconjugated			Half-life extension	Phase 3, Emergency use authorization	COVID-19 (NCT06039449)	Infectious diseases	Invivyd Inc.
XKH004, LZM-012, LZM012		IL-17A, IL-17F	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			TBD	Phase 3	Psoriasis (NCT06110676)	Immune-mediated / inflammatory disorders	Xinkanghe Biomedicine	Livzon Pharmaceutical Group Inc.
YL201		B7-H3	Full length Ab	Monospecific	Human	TBD	TBD	ADC	Tumor Microenviroment Activable Linker	Topoisomerase I inhibitor, YL0010014		Phase 3 pending	Nasopharyngeal Carcinoma (NCT06629597), Small cell lung cancer (NCT06612151)	Cancer	MediLink Therapeutics (Suzhou) Co. Ltd.
ZB001, VRDN-001, IMGN164, AVE1642	Veligrotug	IGF-1R	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			None found	Phase 3	Thyroid Eye Disease (NCT05176639, NCT06021054)	Immune-mediated / inflammatory disorders	Sanofi	Zenas Biopharma, miRagen
ZB012, XMAB5871	Obexelimab	CD19	Full length Ab	Bispecific	Humanized	IgG1	kappa	Unconjugated			S267E, L328F (increase binding to FcγRIIb)	Phase 3	IgG4 Related Disease (NCT05662241); Warm Autoimmune Hemolytic Anemia (NCT05786573)	Immune-mediated / inflammatory disorders	Xencor	Bristol Myers Squibb, Zenas BioPharma Ltd, Amgen
GS-5745	Andecaliximab	MMP9	Full length Ab	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge stabilization)	Phase 3	Fibrodysplasia ossificans progressiva (NCT06508021)	Skeletal disorders	Gilead Sciences Inc	āshibio
REGN1908-1909	Freneslerbart, mevonlerbart	Fel d 1	Full length Ab	Mixture of 2 monospecific antibodies	Humanized	IgG4	kappa	Unconjugated			S228P (hinge stabilization)	Phase 3	Cat allergy (NCT06602726 not yet recruiting)	Immune-mediated / inflammatory disorders	Regeneron Pharmaceuticals	Sanofi
KN057		Tissue factor pathway inhibitor	TBD	Monospecific	TBD	TBD	TBD	Unconjugated			TBD	Phase 3	Hemophilia A and Hemophilia B (NCT06312475, NCT06569108)	Cardiovascular / hemostasis disorders	Suzhou Alphamab Biotechnology Co. Ltd	Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd.
GNR-055	Verenafusp alfa	Insulin receptor	Fragment fusion	Monospecific	Chimeric	NA	kappa	Immunoconjugate		IDS	NA	Phase 2/3	Mucopolysaccharidosis Type II (NCT05208281)	Metabolic disorders	AO GENERIUM
LBL-024		PD-L1, 4-1BB	Appended Ig - scFv-IgG	Bispecific	TBD	TBD	TBD	Unconjugated			TBD	Phase 2 pivotal	Neuroendocrine Carcinoma (NCT06157827)	Cancer	Nanjing Leads Biolabs Co. Ltd
Lu AF82422	Amlenetug	Alpha synuclein	Full length Ab	Monospecific	Human	IgG1	kappa	Unconjugated			None found	Phase 3 pending	Multiple System Atrophy (NCT06706622)	Neurological disorders	H. Lundbeck A/S	Genmab
GR2001		Tetanus toxin	TBD	TBD	TBD	TBD	TBD	Unconjugated			TBD	Phase 3	Tetanus prophylaxis (NCT06635798 / CTR20243076)	Infectious diseases	Genrix (Shanghai) Biopharmaceutical Co., Ltd.
SYS6010, CPO301		EGFR	TBD	Monospecific	TBD	TBD	TBD	ADC		TBD	TBD	Phase 1/3 pending	Non-small cell lung cancer (CTR20243230 not yet recruiting)	Cancer	CSPC Pharmaceutical Group Limited
LP003		IgE	TBD	Monospecific	Humanized	TBD	TBD	Unconjugated			TBD	Phase 3 pending	Seasonal allergic rhinitis (CTR20241964 not yet recruiting)	Immune-mediated / inflammatory disorders	Longbio Pharma (Suzhou) Co. Ltd.	Tianchen Biopharmaceutical (Suzhou) Co. Ltd.
AMG 509	Xaluritamig	STEAP1, CD3	Fragment-Fc	Bispecific	Humanized	TBD	TBD	Unconjugated			S267K (reduced effector function), N293G (no glycosylation), R302C, V302C (additional disulfide bridges)	Phase 3 pending	Prostate cancer (NCT06691984 not yet recruiting)	Cancer	Amgen	Xencor, BeiGene
TQB2102		HER2, HER2	Fragment-Fc conjugate	ADC, Bispecific, Biparatopic	Humanized	TBD	TBD	ADC	Cleavable linker	Topoisomerase I inhibitor	TBD	Phase 3	Breast cancer (NCT06561607 / CTR20242868)	Cancer	Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Sino Biopharmaceutical
TST001, MSB018	Osemitamab	Claudin-18.2	Full length Ab	Monospecific	Humanized	IgG1	kappa	Unconjugated			None found	Phase 3 pending		Cancer	Transcenta Holding Ltd., Maibos Bio
TORL-1-23		Claudin-6	TBD	ADC	TBD	TBD	TBD	ADC	Cleavable linker	Tubulin inhibitor, Monomethyl auristatin E (MMAE)	TBD	Phase 2 pivotal	Ovarian cancer (NCT06690775)	Cancer	TORL Biotherapeutics LLC

Table notes:

in the “Backbone” column, the isotype refers to human unless indicated otherwise with the prefix m- (murine) or r- (rat).
in the “Format” column is reported format and format details.
information on general molecular category (ADC, RIC, immunoconjugates, immunocytokines, unconjugated) and details is reported in the column “Conjugated/Fused”.